Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2015; 36(02): 287-298
DOI: 10.1055/s-0035-1546821
DOI: 10.1055/s-0035-1546821
Cystic Fibrosis Transmembrane Conductance Regulator Modulators: The End of the Beginning
Further Information
Publication History
Publication Date:
31 March 2015 (online)
Abstract
Cystic fibrosis (CF) represents one of the success stories of modern medicine with sustained incremental increases in the survival from one of childhood death to one of adult survival into the middle decades over the past 30 years. Improving survival has focused on multidisciplinary management centered on treating the consequences of this genetic disease. It has been firmly established for more than 20 years that mutations in the CF transmembrane conductance regulator (CFTR) gene result in a defective protein that normally functions as a chloride channel on epithelial cell surfaces. Until recently, modulating CFTR dysfunction was only a research aspiration, however, greater focus placed upon addressing the primary defect of CF has developed several clinical therapeutic strategies in this area. This review highlights the evidence to date on efforts to modulate CFTR and restore robust functional protein to the cell surface. This approach has now led to the licensing of one CFTR potentiator, which has been shown to have significant clinical improvements in a subset of CF patients. This success represents the beginning for CFTR modulation and further research is ongoing which aims to broaden the applicability of these techniques.
-
References
- 1 Andersen DH, Hodges RG. Celiac syndrome: V. Genetics of cystic fibrosis of the pancreas with a consideration of etiology. Am J Dis Child 1946; 72 (1) 62-80
- 2 Riordan JR, Rommens JM, Kerem B-s , et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245 (4922) 1066-1073
- 3 MacKenzie T, Gifford AH, Sabadosa KA , et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med 2014; 161 (4) 233-241
- 4 Conway S, Balfour-Lynn IM, De Rijcke K , et al. European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. J Cyst Fibros 2014; 13: S3-S22
- 5 Hwang TC, Sheppard DN. Gating of the CFTR Cl– channel by ATP‐driven nucleotide‐binding domain dimerisation. J Physiol 2009; 587 (10) 2151-2161
- 6 Castellani C, Cuppens H, Macek Jr M , et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7 (3) 179-196
- 7 Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73 (7) 1251-1254
- 8 Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum Mutat 2002; 19 (6) 575-606
- 9 Anderson MP, Welsh MJ. Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science 1992; 257 (5077) 1701-1704
- 10 Illek B, Zhang L, Lewis NC, Moss RB, Dong J-Y, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol Cell Physiol 1999; 277 (4) C833-C9
- 11 De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 2014; 13 (4) 403-409
- 12 Davies JC, Geddes DM, Alton EW. Gene therapy for cystic fibrosis. J Gene Med 2001; 3 (5) 409-417
- 13 Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002; 54 (11) 1373-1393
- 14 Pedemonte N, Sonawane ND, Taddei A , et al. Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67 (5) 1797-1807
- 15 Pedemonte N, Boido D, Moran O , et al. Structure-activity relationship of 1, 4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol Pharmacol 2007; 72 (1) 197-207
- 16 Yu Y-C, Miki H, Nakamura Y , et al. Curcumin and genistein additively potentiate G551D-CFTR. J Cyst Fibros 2011; 10 (4) 243-252
- 17 Van Goor F, Hadida S, Grootenhuis PD , et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106 (44) 18825-18830
- 18 Van Goor F, Straley KS, Cao D , et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290 (6) L1117-L30
- 19 Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 2012; 287 (44) 36639-36649
- 20 Ramsey BW, Davies J, McElvaney NG , et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365 (18) 1663-1672
- 21 Davies JC, Wainwright CE, Canny GJ , et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013; 187 (11) 1219-1225
- 22 McKone EF, Borowitz D, Drevinek P , et al; VX08-770-105 (PERSIST) Study Group. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014; 2 (11) 902-910
- 23 Rowe SM, Heltshe SL, Gonska T , et al. Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis. Am J Respir Crit Care Med 2014; 190 (2) 175-184
- 24 Barry PJ, Plant BJ, Nair A , et al. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest 2014; 146 (1) 152-158
- 25 Davies JC, Roberston S, Green Y, Rosenfeld M. An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Patients Aged 2 to 5 years with CF and a CFTR Gating Mutation: The KIWI Study. Pediatr Pulmonol 2014; 49 (S38): 286 . Available at: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23108/epdf
- 26 Accurso FJ, Rowe SM, Clancy J , et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363 (21) 1991-2003
- 27 Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8 (1) E101-E11
- 28 de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A. Clin Pharmacokinet 1999; 37 (6) 485-505
- 29 Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 2000; 13 (4) 421-423
- 30 Kalydeco EMA (Ivacaftor) assessment report [cited 2014 28 July]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002494/WC500130766.pdf . Accessed July 28, 2014
- 31 Yu H, Burton B, Huang C-J , et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11 (3) 237-245
- 32 Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 2014; 13 (1) 29-36
- 33 De Boeck K, Munck A, Walker S , et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014; 13 (6) 674-680
- 34 McGarry ME, Nielson DW. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N in vivo response of S549N to ivacaftor. Chest 2013; 144 (4) 1376-1378
- 35 Moss RB, Flume PA, Elborn JS , et al. WS23.6 Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study. J Cyst Fibros 2014; 13: S44
- 36 Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA. Effects of Ivacaftor in CF patients with R117H-CFTR. Pediatr Pulmonol 2014; 49 (S38): S221 . Available at: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23108/epdf
- 37 Nick JA, Rodman D, St Clair C , et al. Effect of Ivacaftor in patients with cystic fibrosis, residual CFTR function, and FEV1 ≥40% of predicted, N-of-1 study. Pediatr Pulmonol 2014; 49 (S38): S285 . Available at: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23108/epdf
- 38 Clancy J, Rowe SM, Accurso FJ , et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67 (1) 12-18
- 39 Goodman N, Watson K, Charlwood J , et al. QBW251 is a novel CFTR Potentiator that has been studies in healthy volunteers. Pediatr Pulmonol 2014; 49 (S38): S232-S233 . Available at: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23108/epdf
- 40 Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients. Available at: http://clinicaltrials.gov/ct2/show/study/NCT02190604 . Accessed November 17, 2014
- 41 Egan ME, Pearson M, Weiner SA , et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304 (5670) 600-602
- 42 Pedemonte N, Tomati V, Sondo E , et al. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J Biol Chem 2011; 286 (17) 15215-15226
- 43 Phuan PW, Yang B, Knapp JM , et al. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol Pharmacol 2011; 80 (4) 683-693
- 44 Van Goor F, Hadida S, Grootenhuis PD , et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108 (46) 18843-18848
- 45 Ren HY, Grove DE, De La Rosa O , et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 2013; 24 (19) 3016-3024
- 46 Cholon DM, Quinney NL, Fulcher ML , et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 2014; 6 (246) 246ra96
- 47 Veit G, Avramescu RG, Perdomo D , et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med 2014; 6 (246) 246ra97
- 48 Sun X, Sui J, Qiu J , et al. Next generation F508Del-CFTR correctors using a YFP based high throughput screening assay. Pediatr Pulmonol 2014; 49 (S38): S216-S217
- 49 Ramachandran S, Osterhaus SR, Karp PH, Welsh MJ, McCray PB. A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function. Am J Respir Cell Mol Biol 2014; 51 (3) 354-362
- 50 Boyle MP, Bell SC, Konstan MW , et al; VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2 (7) 527-538
- 51 Elborn JS, Wainwright CE, Ramsey BW , et al. Effect of Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for F508DEL-CFTR: The TRAFFIC Study. Pediatr Pulmonol 2014; 49 (S38): S304
- 52 Ramsey B, Boyle MP, Elborn J , et al. Effect of Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for F508del-CFTR: TRANSPORT Study. Pediatr Pulmonol 2014; 49 (S38): 305
- 53 Wainwright CE, Elborn JS, Ramsey B , et al. S10.3 Effect of Lumacaftor in combination with Ivacaftor in patients with CF who are homozygous for DelF50d-CFTR: Phase 3 Traffic and Transport Studies. Pediatr Pulmonol 2014; 49 (S38): S156
- 54 Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. Available at: http://investors.vrtx.com/releasedetail.cfm?releaseid=880537 . Accessed November 19, 2014
- 55 Pilewski JM, Donaldson SH, Cooke J, Lekstrom-Himes J. S10.4 Phase 2 Studies Reveal Additive Effects of VX-661, An Investigational CFTR Corrector, and Ivacaftor, A CFTR Potentiator in Patients with CF who carry the DelF508-CFTR Mutation. Pediatr Pulmonol 2014; 49 (S38): S157-S9
- 56 Donaldson S, Pilewski J, Griese M, Dong Q, Lee P-S. WS7. 3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: Interim analysis. J Cyst Fibros 2013; 12 (Suppl. 01) S1-S160
- 57 Donaldson SH, Taylor-Cousar JL, Rosenbluth D , et al. Safety, tolerability, and pharmacokinetics of the intravenous S-nitrosoglutathione reductase inhibitor N6022: an ascending-dose study in subjects homozygous for the F508Del-CFTR mutation. Pediatr Pulmonol 2014; 49 (S38): S308
- 58 Shoemaker S, Madagere A, Troha J, Abbas V, Galloway C, Elhard M. Safety, tolerability, and pharmacokinetics of the oral S-nitrosoglutathione reductase inhibitor N91115: a multiple ascending-dose study in healthy subjects. Pediatr Pulmonol 2014; 49 (S38): S313-S314
- 59 Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2 (4) 467-469
- 60 Clancy JP, Bebök Z, Ruiz F , et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163 (7) 1683-1692
- 61 Wilschanski M, Famini C, Blau H , et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000; 161 (3) 860-865
- 62 Wilschanski M, Yahav Y, Yaacov Y , et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349 (15) 1433-1441
- 63 Sermet-Gaudelus I, Renouil M, Fajac A , et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5 (1) 5
- 64 Clancy JP, Rowe SM, Bebok Z , et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007; 37 (1) 57-66
- 65 Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63 (6) 532-535
- 66 Tan KH-V, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003; 167 (6) 819-823
- 67 Xue X, Mutyam V, Tang L , et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol 2014; 50 (4) 805-816
- 68 EMA. European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/05/WC500167540.pdf . Accessed November 20, 2014
- 69 Kerem E, Konstan MW, De Boeck K , et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014; 2 (7) 539-547
- 70 Yang Y, Li Q, Ertl H, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69 (4) 2004-2015
- 71 Alton E, Stern M, Farley R , et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999; 353 (9157) 947-954
- 72 Armstrong DK, Cunningham S, Davies JC, Alton EWF. Gene therapy in cystic fibrosis. Arch Dis Child 2014; 99 (5) 465-468
- 73 Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes Jr D. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros 2015; 14 (1) 84-89
- 74 Hoare S, McEvoy S, McCarthy CJ , et al. Ivacaftor imaging response in cystic fibrosis. Am J Respir Crit Care Med 2014; 189 (4) 484
- 75 van Beek EJ, Hill C, Woodhouse N , et al. Assessment of lung disease in children with cystic fibrosis using hyperpolarized 3-Helium MRI: comparison with Shwachman score, Chrispin-Norman score and spirometry. Eur Radiol 2007; 17 (4) 1018-1024
- 76 Koumellis P, van Beek EJ, Woodhouse N , et al. Quantitative analysis of regional airways obstruction using dynamic hyperpolarized 3He MRI—preliminary results in children with cystic fibrosis. J Magn Reson Imaging 2005; 22 (3) 420-426
- 77 Mentore K, Froh DK, de Lange EE, Brookeman JR, Paget-Brown AO, Altes TA. Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol 2005; 12 (11) 1423-1429
- 78 Altes T, Johnson M, Higgins M , et al. WS3. 2 The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium-3 MRI, on patients with cystic fibrosis and a G551D-CFTR mutation. J Cyst Fibros 2014; 13: S6
- 79 Davies J, Sheridan H, Bell N , et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 2013; 1 (8) 630-638
- 80 Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85 (2) 229-236
- 81 Laube BL, Sharpless G, Benson J, Carson KA, Mogayzel Jr PJ. Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa. J Pediatr 2014; 164 (4) 839-845
- 82 Hayes Jr D, McCoy KS, Sheikh SI. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Respir Crit Care Med 2014; 190 (4) 468
- 83 Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol 2015; 40 (1) 16-21
- 84 Harrison MJ, Murphy DM, Plant BJ. Ivacaftor in a G551D homozygote with cystic fibrosis. N Engl J Med 2013; 369 (13) 1280-1282
- 85 Gina TC, Hossein S. Resolution of Pancreatic Insufficiency in a Pediatric Patient With Cystic Fibrosis After Initiation of Treatment With Ivacaftor. B25 INTERESTING PEDIATRIC CASES. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2014:A2594-A
- 86 Bellin MD, Laguna T, Leschyshyn J , et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013; 14 (6) 417-421
- 87 Clinical commissioning policy: Ivacaftor for Cystic Fibrosis NHS commissioning Board. Available at: http://www.england.nhs.uk/wp-content/uploads/2013/04/a01-p-b/pdf . Accessed November 10, 2014
- 88 Barry PJ, Jones AM, Webb AK, Horsley AR. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Thorax 2014; 69 (6) 586-587
- 89 Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials sweat chloride as a study end point the ivacaftor experience. Chest 2013; 143 (1) 14-18
- 90 Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 2013; 12 (6) 706-713
- 91 Bush A, Simmonds NJ. Hot off the breath: ‘I’ve a cost for'—the 64 million dollar question. Thorax 2012; 67 (5) 382-384
- 92 O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot?. JAMA 2013; 310 (13) 1343-1344
- 93 Dekkers JF, Wiegerinck CL, de Jonge HR , et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19 (7) 939-945
- 94 Dekkers R, Vijftigschild LA, Vonk AM , et al. A bioassay using intestinal organoids to measure CFTR modulators in human plasma. J Cyst Fibros 2014;
- 95 Ramsey BW, Pepe MS, Quan JM , et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340 (1) 23-30
- 96 Saiman L, Marshall BC, Mayer-Hamblett N , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290 (13) 1749-1756
- 97 Quittner AL, Zhang J, Marynchenko M , et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014; 146 (1) 142-151